1/ At first glance the departure of Jason Myers, CEO of ArcherDx that was acquired by $NVTA, seems like a big negative. It was a large acquisition for $NVTA & Jason was leading $NVTA's oncology business. Jason will be joining GenapSys as the CEO. He will remain on $NVTA's board.
2/ What does GenapSys do? They are developing Sequencers that utilizes "the first ever purely electrical sequencing chip, the key component in our fully integrated proprietary platform". They are focused on cost reduction and building scalable systems.
3/ Gene/Genome sequencing is the starting point for $NVTA diagnostics & monitoring solutions. A key application for GenapSys is "targeted sequencing" which is critical for Oncology. $NVTA is focused on reducing diagnostic costs, but is defendant on the sequencing partner.
You can follow @JessieChimni.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.